Nuvation Bio expands glioma drug trial to six European nations
Nuvation Bio (NYSE:NUVB) expanded its Phase 3 SIGMA trial of safusidenib to six European countries, adding to existing sites in the U.S., Australia, China, Canada, and Japan. The study evaluates safusidenib as maintenance therapy for IDH1-mutant astrocytoma, with a primary endpoint of progression-free survival. The trial plans to enroll 300 patients, with an exploratory cohort of 40. The FDA granted Fast Track Designation to safusidenib in August 2026.
How this was made
The 30-second read
Why it matters
The expansion adds six new countries, increasing total enrollment to ~340 patients, enhancing data robustness.
Market read
Primary biotech news with potential upside for NUVB; modest sector ripple.
What to watch
Regulatory timelines in Europe and potential competition from other IDH1 inhibitors.
Background
NUVB is a NYSE‑listed biotech developing safusidenib for IDH1‑mutant glioma, previously granted Fast Track status.
Ticker impact
NUVB announced expansion of its Phase 3 SIGMA trial to six additional European countries, adding new sites and patients.
likely upward pressure as investors price in expanded trial reach and potential future data readouts
Trial site additions increase patient enrollment capacity and market exposure, a material catalyst for a biotech.
Market effects
May boost sentiment for IDH1‑mutant glioma therapeutics and related biotech peers.
European markets may see modest interest in biotech stocks tied to clinical expansion.
Limited to biotech sector; not a broad market mover.
Counterpoint
Trial expansion could dilute focus and increase costs without guaranteeing positive data.
Key entities
- companyNuvation Bio Inc.
Developer of safusidenib, listed as NUVB.
- regulatorFDA
Granted Fast Track designation for safusidenib in August 2026.
